{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:28:34Z","timestamp":1789748914062,"version":"4.0.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shenzhen Medical Research Fund","award":["C2401003"],"award-info":[{"award-number":["C2401003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Stereotactic body radiotherapy (SBRT) is a highly effective and well-tolerated treatment modality for peripherally located early-stage non-small cell lung cancer as well as pulmonary metastases. However, its feasibility and safety remain uncertain in patients with ultra-central (UC) lung tumors. This study aims to evaluate the efficacy and safety of SBRT in the management of UC lung malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review of the available literature was conducted in accordance with the PRISMA guidelines, incorporating studies that reported both treatment-related side effects and therapeutic efficacy associated with SBRT for UC lung malignancies. Patient characteristics, prescription doses, local control (LC), overall survival (OS), and side effects information were extracted. Clinical outcomes were analyzed using the random-effects model. Meta-regression was conducted to determine the effect of various covariates on LC and OS outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-three articles with a total of 1,105 patients were included. Pooled 1- and 2-year LC rates were 93% (95% CI: 88\u201396%) and 84% (95% CI: 77\u201389%), respectively. Meta-regression demonstrated a significantly positive association between BED\n                      <jats:sub>10<\/jats:sub>\n                      and 1- and 2-year LC rates (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001, respectively), and a significantly negative association between PTV volume and 1- and 2-year LC (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.048,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.030, respectively). Pooled 1- and 2-year OS rates were 81% (95% CI: 77\u201385%) and 58% (95% CI: 52\u201364%), respectively. Meta-regression revealed a significantly positive association between BED\n                      <jats:sub>10<\/jats:sub>\n                      and 1- and 2-year OS rates (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.025,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002, respectively), and a significantly negative association between PTV volume and 1- and 2-year OS (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.031,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001, respectively). The pooled rates of grade\u2009\u2265\u20093 and grade 5 treatment-related side effects were 9% (95% CI: 6\u201314%) and 2% (95% CI: 1\u20135%), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This meta-analysis demonstrates that SBRT achieves favorable LC rates and is a relatively safe treatment for UC lung malignancies. Although the pooled rate of grade 5 side effects, at 2%, was within an acceptable range, vigilance remains essential. Further prospective research is warranted to verify our conclusions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-026-02854-5","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T03:55:11Z","timestamp":1778471711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Stereotactic body radiation therapy for ultra-central lung malignancies: an updated systematic review and meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Hai","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Churong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2854_CR1","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","volume":"402","author":"JY Chang","year":"2023","unstructured":"Chang JY, Lin SH, Dong W, et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023;402:871\u201381.","journal-title":"Lancet"},{"key":"2854_CR2","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/S1470-2045(21)00401-0","volume":"22","author":"JY Chang","year":"2021","unstructured":"Chang JY, Mehran RJ, Feng L, et al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021;22:1448\u201357.","journal-title":"Lancet Oncol"},{"key":"2854_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/cncr.31196","volume":"124","author":"DJ Tandberg","year":"2018","unstructured":"Tandberg DJ, Tong BC, Ackerson BG, Kelsey CR. Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. Cancer. 2018;124:667\u201378.","journal-title":"Cancer"},{"key":"2854_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13014-015-0423-7","volume":"10","author":"KD Kelley","year":"2015","unstructured":"Kelley KD, Benninghoff DL, Stein JS, et al. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy. Radiat Oncol. 2015;10:120.","journal-title":"Radiat Oncol"},{"key":"2854_CR5","doi-asserted-by":"publisher","first-page":"109804","DOI":"10.1016\/j.radonc.2023.109804","volume":"186","author":"X Wang","year":"2023","unstructured":"Wang X, Bai H, Gao M, et al. Impact of radiation dose to the immune system on disease progression and survival for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy. Radiother Oncol. 2023;186:109804.","journal-title":"Radiother Oncol"},{"key":"2854_CR6","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.prro.2015.09.012","volume":"6","author":"JM Haseltine","year":"2016","unstructured":"Haseltine JM, Rimner A, Gelblum DY, et al. Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. Pract Radiat Oncol. 2016;6:e27\u201333.","journal-title":"Pract Radiat Oncol"},{"key":"2854_CR7","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/j.jtho.2024.09.1386","volume":"19","author":"HS Park","year":"2024","unstructured":"Park HS, Rimner A, Amini A, et al. Appropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central\/Ultra-Central Location: Guidelines from the American Radium Society. J Thorac Oncol. 2024;19:1640\u201353.","journal-title":"J Thorac Oncol"},{"key":"2854_CR8","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","volume":"24","author":"R Timmerman","year":"2006","unstructured":"Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833\u20139.","journal-title":"J Clin Oncol"},{"key":"2854_CR9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.radonc.2013.01.004","volume":"106","author":"S Senthi","year":"2013","unstructured":"Senthi S, Haasbeek CJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol. 2013;106:276\u201382.","journal-title":"Radiother Oncol"},{"key":"2854_CR10","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1200\/JCO.18.00622","volume":"37","author":"A Bezjak","year":"2019","unstructured":"Bezjak A, Paulus R, Gaspar LE, et al. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology\/RTOG 0813 Trial. J Clin Oncol. 2019;37:1316\u201325.","journal-title":"J Clin Oncol"},{"key":"2854_CR11","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.jtho.2019.04.018","volume":"14","author":"H Chen","year":"2019","unstructured":"Chen H, Laba JM, Zayed S, et al. Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review. J Thorac Oncol. 2019;14:1332\u201342.","journal-title":"J Thorac Oncol"},{"key":"2854_CR12","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","volume":"16","author":"K Lindberg","year":"2021","unstructured":"Lindberg K, Grozman V, Karlsson K, et al. The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy. J Thorac Oncol. 2021;16:1200\u201310.","journal-title":"J Thorac Oncol"},{"key":"2854_CR13","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.ijrobp.2023.06.246","volume":"117","author":"S Lindberg","year":"2023","unstructured":"Lindberg S, Grozman V, Karlsson K, et al. Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors. Int J Radiat Oncol Biol Phys. 2023;117:1222\u201331.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2854_CR14","doi-asserted-by":"publisher","first-page":"107281","DOI":"10.1016\/j.lungcan.2023.107281","volume":"182","author":"M Yan","year":"2023","unstructured":"Yan M, Louie AV, Kotecha R, et al. Stereotactic body radiotherapy for Ultra-Central lung Tumors: A systematic review and Meta-Analysis and International Stereotactic Radiosurgery Society practice guidelines. Lung Cancer. 2023;182:107281.","journal-title":"Lung Cancer"},{"key":"2854_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178\u201389.","journal-title":"J Clin Epidemiol"},{"key":"2854_CR16","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1001\/jamadermatol.2019.2941","volume":"155","author":"M Zidane","year":"2019","unstructured":"Zidane M, Dressler C, Gaskins M, Nast A. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis. JAMA Dermatol. 2019;155:1380\u20139.","journal-title":"JAMA Dermatol"},{"key":"2854_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.7326\/M19-3286","volume":"172","author":"DE Kloecker","year":"2020","unstructured":"Kloecker DE, Davies MJ, Khunti K, Zaccardi F. Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. Ann Intern Med. 2020;172:541\u201352.","journal-title":"Ann Intern Med"},{"key":"2854_CR18","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"2854_CR19","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","volume":"61","author":"JL Peters","year":"2008","unstructured":"Peters JL, Sutton AJ, Jones DR, et al. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61:991\u20136.","journal-title":"J Clin Epidemiol"},{"key":"2854_CR20","doi-asserted-by":"crossref","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315.","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2854_CR21","doi-asserted-by":"publisher","first-page":"10916","DOI":"10.1002\/ece3.6747","volume":"10","author":"CJ Lortie","year":"2020","unstructured":"Lortie CJ, Filazzola A. A contrast of meta and metafor packages for meta-analyses in R. Ecol Evol. 2020;10:10916\u201321.","journal-title":"Ecol Evol"},{"key":"2854_CR22","doi-asserted-by":"crossref","unstructured":"Farrugia M, Ma SJ, Hennon M, et al. Exceeding radiation dose to volume parameters for the proximal airways with stereotactic body radiation therapy is more likely for ultracentral lung tumors and associated with worse outcome. Cancers (Basel). 2021;13.","DOI":"10.3390\/cancers13143463"},{"key":"2854_CR23","doi-asserted-by":"crossref","unstructured":"Salvestrini V, Duijm M, Loi M, Nuyttens JJ. Survival and prognostic factors of ultra-central tumors treated with stereotactic body radiotherapy. Cancers (Basel). 2022;14.","DOI":"10.3390\/cancers14235908"},{"key":"2854_CR24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/0284186X.2021.1942545","volume":"60","author":"JE Lodeweges","year":"2021","unstructured":"Lodeweges JE, van Rossum PSN, Bartels M, et al. Ultra-central lung tumors: safety and efficacy of protracted stereotactic body radiotherapy. Acta Oncol. 2021;60:1061\u20138.","journal-title":"Acta Oncol"},{"key":"2854_CR25","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","volume":"11","author":"H Tekatli","year":"2016","unstructured":"Tekatli H, Haasbeek N, Dahele M, et al. Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with Ultracentral Non\u2013Small Cell Lung Cancer. J Thorac Oncol. 2016;11:1081\u20139.","journal-title":"J Thorac Oncol"},{"key":"2854_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13014-016-0608-8","volume":"11","author":"JW Lischalk","year":"2016","unstructured":"Lischalk JW, Malik RM, Collins SP, et al. Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases. Radiat Oncol. 2016;11:28.","journal-title":"Radiat Oncol"},{"key":"2854_CR27","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.cllc.2020.11.003","volume":"22","author":"S Regnery","year":"2021","unstructured":"Regnery S, Eichkorn T, Weykamp F, et al. Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme. Clin Lung Cancer. 2021;22:332\u2013e340333.","journal-title":"Clin Lung Cancer"},{"key":"2854_CR28","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.clon.2021.05.005","volume":"33","author":"AM Mihai","year":"2021","unstructured":"Mihai AM, Armstrong PJ, Hickey D, et al. Late toxicity and long-term local control in patients with ultra-central lung tumours treated by intensity-modulated radiotherapy-based stereotactic ablative body radiotherapy with homogenous dose prescription. Clin Oncol (R Coll Radiol). 2021;33:627\u201337.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2854_CR29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.radonc.2021.03.001","volume":"158","author":"WG Breen","year":"2021","unstructured":"Breen WG, Jeans EB, Gergelis KR, et al. Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity. Radiother Oncol. 2021;158:246\u201352.","journal-title":"Radiother Oncol"},{"key":"2854_CR30","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/1759-7714.13105","volume":"10","author":"Y Cong","year":"2019","unstructured":"Cong Y, Sun B, Wang J, et al. Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer. Thorac Cancer. 2019;10:1567\u201375.","journal-title":"Thorac Cancer"},{"key":"2854_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.tipsro.2020.01.002","volume":"13","author":"R Cooke","year":"2020","unstructured":"Cooke R, Camilleri P, Chu KY, et al. Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: Initial outcomes. Tech Innov Patient Support Radiat Oncol. 2020;13:24\u201330.","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"key":"2854_CR32","doi-asserted-by":"publisher","first-page":"20210533","DOI":"10.1259\/bjr.20210533","volume":"95","author":"E Guillaume","year":"2022","unstructured":"Guillaume E, Tanguy R, Ayadi M, et al. Toxicity and efficacy of stereotactic body radiotherapy for ultra-central lung tumours: a single institution real life experience. Br J Radiol. 2022;95:20210533.","journal-title":"Br J Radiol"},{"key":"2854_CR33","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s00066-020-01687-9","volume":"197","author":"M Loi","year":"2021","unstructured":"Loi M, Franceschini D, Dominici L, et al. Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy. Strahlenther Onkol. 2021;197:396\u2013404.","journal-title":"Strahlenther Onkol"},{"key":"2854_CR34","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/j.prro.2018.11.005","volume":"9","author":"KNB Nguyen","year":"2019","unstructured":"Nguyen KNB, Hause DJ, Novak J, et al. Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors. Pract Radiat Oncol. 2019;9:e196\u2013202.","journal-title":"Pract Radiat Oncol"},{"key":"2854_CR35","doi-asserted-by":"publisher","first-page":"e803","DOI":"10.1016\/j.cllc.2018.06.001","volume":"19","author":"S Raman","year":"2018","unstructured":"Raman S, Yau V, Pineda S, et al. Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience. Clin Lung Cancer. 2018;19:e803\u201310.","journal-title":"Clin Lung Cancer"},{"key":"2854_CR36","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/1759-7714.13335","volume":"11","author":"D Yang","year":"2020","unstructured":"Yang D, Cui J, Zhao J, et al. Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non-small cell lung cancer. Thorac Cancer. 2020;11:754\u201361.","journal-title":"Thorac Cancer"},{"key":"2854_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13014-020-01491-w","volume":"15","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Khawandanh E, Thomas S, et al. Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors. Radiat Oncol. 2020;15:61.","journal-title":"Radiat Oncol"},{"key":"2854_CR38","doi-asserted-by":"publisher","first-page":"868844","DOI":"10.3389\/fonc.2022.868844","volume":"12","author":"B Wang","year":"2022","unstructured":"Wang B, Dong Y, Yu X, et al. Safety and Efficacy of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Cancer. Front Oncol. 2022;12:868844.","journal-title":"Front Oncol"},{"key":"2854_CR39","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ijrobp.2024.03.050","volume":"120","author":"ME Giuliani","year":"2024","unstructured":"Giuliani ME, Filion E, Faria S, et al. Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET). Int J Radiat Oncol Biol Phys. 2024;120:669\u201377.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2854_CR40","doi-asserted-by":"publisher","first-page":"110034","DOI":"10.1016\/j.radonc.2023.110034","volume":"190","author":"G Lee","year":"2024","unstructured":"Lee G, Han Z, Huynh E, et al. Widening the therapeutic window for central and ultra-central thoracic oligometastatic disease with stereotactic MR-guided adaptive radiation therapy (SMART). Radiother Oncol. 2024;190:110034.","journal-title":"Radiother Oncol"},{"key":"2854_CR41","doi-asserted-by":"publisher","first-page":"107175","DOI":"10.1016\/j.lungcan.2023.03.011","volume":"179","author":"S Regnery","year":"2023","unstructured":"Regnery S, Katsigiannopulos E, Hoegen P, et al. To fly or not to fly: Stereotactic MR-guided adaptive radiotherapy effectively treats ultracentral lung tumors with favorable long-term outcomes. Lung Cancer. 2023;179:107175.","journal-title":"Lung Cancer"},{"key":"2854_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1756-8722-3-39","volume":"3","author":"K Unger","year":"2010","unstructured":"Unger K, Ju A, Oermann E, et al. CyberKnife for hilar lung tumors: report of clinical response and toxicity. J Hematol Oncol. 2010;3:39.","journal-title":"J Hematol Oncol"},{"key":"2854_CR43","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","volume":"2","author":"H Onishi","year":"2007","unstructured":"Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2:S94\u2013100.","journal-title":"J Thorac Oncol"},{"key":"2854_CR44","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.21037\/tlcr-20-503","volume":"9","author":"CH Rim","year":"2020","unstructured":"Rim CH, Shin IS, Yoon WS, Park S. Dose-response relationship of stereotactic body radiotherapy for ultracentral tumor and comparison of efficacy with central tumor: a meta-analysis. Transl Lung Cancer Res. 2020;9:1268\u201384.","journal-title":"Transl Lung Cancer Res"},{"key":"2854_CR45","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijrobp.2006.11.051","volume":"68","author":"L Zhao","year":"2007","unstructured":"Zhao L, West BT, Hayman JA, et al. High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer. Int J Radiation Oncology*Biology*Physics. 2007;68:103\u201310.","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"key":"2854_CR46","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.radonc.2020.11.021","volume":"154","author":"G Dupic","year":"2021","unstructured":"Dupic G, Brun L, Molnar I, et al. Significant correlation between gross tumor volume (GTV) D98% and local control in multifraction stereotactic radiotherapy (MF-SRT) for unresected brain metastases. Radiother Oncol. 2021;154:260\u20138.","journal-title":"Radiother Oncol"},{"key":"2854_CR47","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fimmu.2019.00407","volume":"10","author":"F Eckert","year":"2019","unstructured":"Eckert F, Zwirner K, Boeke S, et al. Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors. Front Immunol. 2019;10:407.","journal-title":"Front Immunol"},{"key":"2854_CR48","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.radonc.2023.109951","volume":"189","author":"RM Hill","year":"2023","unstructured":"Hill RM, Fok M, Grundy G, et al. The role of autophagy in hypoxia-induced radioresistance. Radiother Oncol. 2023;189:8.","journal-title":"Radiother Oncol"},{"key":"2854_CR49","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ijrobp.2011.04.027","volume":"81","author":"Y Dai","year":"2011","unstructured":"Dai Y, Bae K, Siemann DW. Impact of Hypoxia on the Metastatic Potential of Human Prostate Cancer Cells. Int J Radiat Oncol Biol Phys. 2011;81:521\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2854_CR50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.radonc.2013.09.005","volume":"109","author":"M Guckenberger","year":"2013","unstructured":"Guckenberger M, Klement RJ, Allg\u00e4uer M, et al. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer. Radiother Oncol. 2013;109:13\u201320.","journal-title":"Radiother Oncol"},{"key":"2854_CR51","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.radonc.2015.09.008","volume":"118","author":"M Guckenberger","year":"2016","unstructured":"Guckenberger M, Klement RJ, Allg\u00e4uer M, et al. Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. Radiother Oncol. 2016;118:485\u201391.","journal-title":"Radiother Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02854-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02854-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02854-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:22:15Z","timestamp":1781756535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02854-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2854"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02854-5","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a systematic review of previously published data. Therefore, ethical approval was not required. This review performed in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have read and approved the manuscript. We have no financial disclosures. We are not using any copyrighted information, patient photographs, identifiers, or other protected health information in this paper. No text, text boxes, figures, or tables in this article have been previously published or owned by another party.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Approval\/disclosures"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}